News

404

Bobby W. Sandage, Jr., Ph.D.

Bobby W. Sandage, Jr., Ph.D.

CHAIRMAN

Dr. Sandage has over 35 years of experience in the pharmaceutical industry in drug development and senior management and currently Managing Director of the Riney Family Foundation and General Partner in Cultivation Capital Life Sciences Fund II.

Previously he was President and Chief Executive Officer of Coronado BioSciences, Inc. (NASD: CNDO), where he took the company public in 2011. Prior to that, he was VP of CovidienPharmaceuticals’ oncology research and development program. For 19 years, Dr. Sandage was the CSO and EVP of R&D, Quality and Manufacturing at Indevus Pharmaceuticals, Inc. (NASD: IDEV) which was acquired by Endo Pharmaceuticals in 2009. Prior to Indevus, he held senior drug development positions at DuPont Merck Pharmaceutical Company and Merrell Dow and Dow Pharmaceuticals.

CHAIRMAN

Dr. Sandage has over 35 years of experience in the pharmaceutical industry in drug development and senior management and currently Managing Director of the Riney Family Foundation and General Partner in Cultivation Capital Life Sciences Fund II.

Previously he was President and Chief Executive Officer of Coronado BioSciences, Inc. (NASD: CNDO), where he took the company public in 2011. Prior to that, he was VP of CovidienPharmaceuticals’ oncology research and development program. For 19 years, Dr. Sandage was the CSO and EVP of R&D, Quality and Manufacturing at Indevus Pharmaceuticals, Inc. (NASD: IDEV) which was acquired by Endo Pharmaceuticals in 2009. Prior to Indevus, he held senior drug development positions at DuPont Merck Pharmaceutical Company and Merrell Dow and Dow Pharmaceuticals.

Scroll to top